J&J’s therapy combination of antibody treatment Rybrevant and experimental drug lazertinib showed a clinically meaningful improvement in progression-free survival rate in patients.
The companies on Wednesday secured the regulator’s approval for their eye drop Ryzvumi for the reversal of pharmacologically-induced mydriasis, as Viatris looks to add $1 billion in sales by 2028.
Today the company lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating the infection.
The US Food and Drug Administration received more than 250 reports of patients experiencing suicidal thoughts or behaviors while taking Ozempic or similar medicines since 2010, Reuters found in an examination of the FDA’s adverse-event database.
The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending a decision by the federal patent court on a lawsuit filed by BioNTech.
Reuters HealthAn antibiotic already in use in Europe to treat pneumonia controlled deadly bloodstream infections with Staphylococcus aureus bacteria just as effectively as the most powerful antibiotic currently in use, according to data from a late-stage trial.
Soon after cancelling its contract with I-Mab, AbbVie has now also turned its back on a partnership with Berkeley-based Caribou Biosciences that was focused on advancing allogeneic CAR-T therapeutics.
European drugmakers warned that a proposed complete ban on substances known as PFAS or “forever chemicals” would render medicine production in the region impossible, part of a high-stakes wrangle between manufacturers and environmental regulators.
The dual role of chemicals in both R&D and manufacturing means that chemical procurement is critical to keeping biopharma companies operating smoothly. A reliable and robust chemical supply chain is essential for both phases, as disruptions can have ripple effects that impact not just timelines and costs, but also the quality and safety of the end products.
Despite filing respective lawsuits challenging the program, AstraZeneca and Bristol Myers Squibb have decided to participate in the first round of price negotiations under the Inflation Reduction Act.